Upon joining the study, you will attend an initial visit. During this visit, your current health status will be assessed, and you will complete a self-report questionnaire on attention and memory, known as the FEDA.

Your quality of life will be measured using a questionnaire called SF36. Additionally, a close relative, partner, or care provider will assess your everyday executive function using the BAFQ.

You will be assigned to take one of two formulations of the medication tacrolimus. This medication is used to help prevent organ rejection after a liver transplant.

If you are assigned to the twice-daily formulation, you will take Prograf capsules, which come in doses of 0.5 mg, 1 mg, or 5 mg. If you are assigned to the once-daily formulation, you will take Envarsus prolonged-release tablets, which come in doses of 0.75 mg, 1 mg, or 4 mg.

You will have follow-up visits at 6 months and 12 months after the initial visit. During these visits, your cognitive function will be assessed using several tests, including the Trail Making Test, Adaptive Digit Ordering Test, Digit Symbol Test, Regensburg Stream of Speech Test, and Victoria Stroop Test.

Your quality of life will be reassessed using the SF36 questionnaire, and your everyday executive function will be reassessed using the BAFQ.

Throughout the trial, any significant changes in your health, including adverse events and laboratory results, will be documented at each visit.

Your liver and kidney function will be monitored to ensure your safety while taking the medication.